Fig. 1 · Structure

Documents & Downloads

Navitoclax (ABT-263)

Cat. No. A10022 CAS 923564-51-6

Bcl-2 inhibitor

ABT-263 also called Navitoclax is a potent and orally bioavailable Bcl-2 family inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). it maintains a high affinity for Bcl-xL, Bcl-2, and Bcl-w, (Ki ≤1 nmol/L), but binds more weakly to Mcl-1 and A1.

In Stock

Publications for Navitoclax

26 publications citing this product

  1. Mikako Hirose, .et al. , Biosci Biotechnol Biochem, 2025, Dec 18;90(1):76-87 PMID: 41134023
  2. Song Han, .et al. , Neoplasia, 2025, Jan:59:101070 PMID: 39541736
  3. Abdel-Aziz S Shatat, .et al. , Purinergic Signal, 2024, May 27 PMID: 38801618
  4. Tristen Wright, .et al. , Mol Cell, 2024, Apr 4;84(7):1338-1353 PMID: 38503284
  5. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
  6. Yibo Wen, .et al. , Ren Fail, 2023, Dec;45(1):2194440 PMID: 37154092
  7. Rindert Missiaen, .et al. , Cell Metab, 2022, Aug 2;34(8):1151-1167 PMID: 35839757
  8. Ashlyn Parkhurst, .et al. , Cell Death Dis, 2022, Apr 28;13(4):410 PMID: 35484114
  9. Suzuki, Keiji, .et al. , Mutat Res Genet Toxicol Environ Mutagen, 2022, 876-877. 503448 PMID: 35483779
  10. Rotem Ben-Hamo, .et al. , Nat Commun, 2020, 11: 3296 PMID: 32620799

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

ABT-263 (navitoclax) binds the anti-apoptotic proteins Bcl-2 and Bcl-xL. The original discovery supplement reports Ki <1 nM for both targets. These biochemical affinities do not define a recommended cellular concentration. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Bcl-xL (Cell-free assay) Ki <=0.5 nM
Bcl-2 (Cell-free assay) Ki <=1 nM
Bcl-w (Cell-free assay) Ki <=1 nM
A1 (Cell-free assay) Ki 354 nM
Mcl-1 (Cell-free assay) Ki 550 nM

Cellular Effect

Cell Line Activity Value Description Reference
FL5.12 EC50 4.2 nM Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum [PMID: 18841882]
FL5.12 EC50 5.9 nM Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum [PMID: 18841882]
MOLT-4 EC50 0.3 μM Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability measured after 48 hrs by celltiter-glo assay [PMID: 34141086]
MOLT-4 IC50 212.3 nM Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay [PMID: 34533954]
NCI-H1417 IC50 54.2 nM Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay [PMID: 23448298]
NCI-H146 EC50 0.08 μM Cytotoxicity against human NCI-H146 after 48 hrs by MTS assay in presence of 10% human serum [PMID: 21366295]
NCI-H146 EC50 86.7 nM Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum [PMID: 18841882]
NCI-H187 IC50 38.4 nM Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay [PMID: 23448298]
NCI-H1963 EC50 0.051 μM Cytotoxicity against human NCI-H1963 after 48 hrs by MTS assay in presence of 10% human serum [PMID: 21366295]
NCI-H1963 IC50 26.6 nM Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay [PMID: 23448298]
NCI-H889 EC50 0.12 μM Cytotoxicity against human NCI-H889 after 48 hrs by MTS assay in presence of 10% human serum [PMID: 21366295]
Platelet IC50 0.189 μM Cytotoxicity against human platelet assessed as cell viability measured after 72 hrs by MTS assay [PMID: 32388279]
Platelet IC50 0.325 μM Cytotoxicity against platelets in human PRP assessed as reduction in cell viability measured after 48 hrs by MTS assay [PMID: 34533954]
RS4-11 EC50 0.014 μM Induction of apoptosis in human RS4:11 cells overexpressing BCL-2 assessed as caspase 3/7 activation after 6 hrs by quantitative luminescence assay [PMID: 24881567]
RS4-11 EC50 0.11 μM Cytotoxicity against human RS4-11 cells assessed as reduction in cell viability measured after 48 hrs by celltiter-glo assay [PMID: 34141086]
RS4-11 IC50 42.6 nM Cytotoxicity against human RS4-11 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay [PMID: 34533954]
WI-38 IC50 8.06 μM Cytotoxicity against human WI-38 cells assessed as cell viability measured after 72 hrs by MTS assay [PMID: 32388279]

17 records · Scroll to view more

Navitoclax (ABT-263) Research Summary

This section summarizes 4 in vitro studies and 3 in vivo studies of Navitoclax (ABT-263) from 5 published references. In vitro models include Bcl-2 and Bcl-xL binding assays; PLC/PRF/5, Hep3B, HepG2 and Huh7 hepatocellular carcinoma cells.

Navitoclax (ABT-263) In Vitro Studies

Cellular response depends on the model. Across 39 human non-Hodgkin lymphoma cell lines, higher BCL-2 and NOXA expression correlated with navitoclax sensitivity, whereas higher MCL-1 correlated with resistance. BCL-X and BCL-W expression did not significantly correlate with response in this panel. [2]

In four hepatocellular carcinoma cell lines, 5 μM ABT-263 for 18 h increased Mcl-1 protein. Mcl-1 depletion enhanced the viability loss seen after a separate 36 h exposure. In PLC/PRF/5 cells, 12 h pretreatment with 5 μM ABT-263 slowed Mcl-1 loss during a cycloheximide chase; the reported protein half-life increased from 30 min to more than 4 h. [3]

Binding affinity for Bcl-2 and Bcl-xL

Biochemical assay · Bcl-2 and Bcl-xL binding assays [1]

The original supporting table reports Ki <1 nM for both targets for compound 2 (ABT-263).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Bcl-2 binding affinityKi < 1 nM[1]
Bcl-xL binding affinityKi < 1 nM[1]

Literature-Reported Treatment Conditions

Reported limits
Main binding assay protocol, tested concentration range, incubation time, vehicle, replicate count and uncertainty were not available in the retrieved SI. Ki values are measurements, not treatment recommendations.
Methods and source locations

Compound reported in the paper: ABT-263 (Navitoclax); Compound label in the paper: 2 (ABT-263)

Compound-level research evidence; no batch, polymorph or Adooq validation claim.

Supporting information Table S1, pp. S2-S3, compound 2 row; Table S2 p. S4; main abstract compound-number mapping

Bcl-2 binding affinity — Supporting information Table S1, pp. S2-S3, compound 2 row; Table S2 p. S4; main abstract compound-number mapping

Bcl-xL binding affinity — Supporting information Table S1, pp. S2-S3, compound 2 row; Table S2 p. S4; main abstract compound-number mapping

Mcl-1 accumulation and response to Mcl-1 depletion

Cell-based study · PLC/PRF/5, Hep3B, HepG2 and Huh7 hepatocellular carcinoma cells [3]

ABT-263 increased Mcl-1 protein without an evident change in Bcl-2 or Bcl-xL. Mcl-1 depletion enhanced the loss of viability during ABT-263 treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mcl-1, Bcl-2 and Bcl-xL protein abundanceQualitative immunoblot result Mcl-1 increased; Bcl-2 and Bcl-xL did not change significantly (authors’ description).[3]
Cell viability after Mcl-1 siRNA or control siRNA followed by ABT-263 or DMSORelative cell viability Mcl-1 siRNA enhanced ABT-263 cytotoxicity; mean ± SD, three independent experiments; exact bar values not tabulated.[3]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
18 h for protein expression; 36 h after 24 h siRNA transfection for viability
Method
Cell culture in high-glucose DMEM with 10% FBS; Western blot and CCK-8
Vehicle
DMSO control explicitly specified for viability experiment; final fraction not stated in reviewed material
Co-treatment
Mcl-1 siRNA versus control siRNA in the viability experiment; separate ABT-263-only protein-expression experiment
Reported limits
siRNA concentration and final DMSO fraction not specified in the reviewed experiment. Immunoblot replicate count not stated; viability n=3 independent experiments.
Methods and source locations

Compound reported in the paper: ABT-263 (Navitoclax); Compound label in the paper: ABT-263

Compound-level research evidence; no batch, polymorph or Adooq validation claim.

Figure 1B and 1D-E; Results: Upregulation of Mcl-1 is correlated with ABT-263 resistance in HCC cells; Methods: Cell culture, Western blot, Cell viability assay

Mcl-1, Bcl-2 and Bcl-xL protein abundance: Western blot; α-tubulin loading control; 5 μM ABT-263 for 18 h — Figure 1B and corresponding Results

Cell viability after Mcl-1 siRNA or control siRNA followed by ABT-263 or DMSO: CCK-8; optical density at 450 nm; siRNA for 24 h then 5 μM ABT-263 or DMSO for 36 h — Figure 1D-E and legend

Mcl-1 protein stability during cycloheximide treatment

Cell-based study · PLC/PRF/5 hepatocellular carcinoma cells [3]

ABT-263 pretreatment slowed Mcl-1 protein loss during a cycloheximide chase.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mcl-1 protein half-life after DMSO pretreatmentProtein half-life 30 min[3]
Mcl-1 protein half-life after ABT-263 pretreatmentProtein half-life more than 4 h[3]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM ABT-263; 10 μM cycloheximide
Exposure duration
12 h ABT-263/DMSO pretreatment; chase at 0, 15, 30, 60, 120 and 240 min
Method
Western blot protein-decay time course
Vehicle
DMSO; final fraction not specified
Co-treatment
Cycloheximide blocks protein synthesis; compare ABT-263 and DMSO pretreatment
Reported limits
No numerical uncertainty or fitted half-life confidence interval is reported. Continued ABT-263 exposure during the chase is not explicit in the figure legend.
Methods and source locations

Compound reported in the paper: ABT-263 (Navitoclax); Compound label in the paper: ABT-263

Compound-level research evidence; no batch, polymorph or Adooq validation claim.

Figure 4A-B and legend; Results: ABT-263 increases the protein stability of Mcl-1; Methods: Western blot

Mcl-1 protein half-life after DMSO pretreatment: 10 μM cycloheximide chase; immunoblot Mcl-1 normalized to α-tubulin and the corresponding CHX 0 min sample — Figure 4A-B and legend; Results: ABT-263 increases the protein stability of Mcl-1; Methods: Western blot

Mcl-1 protein half-life after ABT-263 pretreatment: 5 μM ABT-263 for 12 h before 10 μM cycloheximide; mean ± SD from three independent experiments for relative abundance — Figure 4A-B and legend; Results: ABT-263 increases the protein stability of Mcl-1; Methods: Western blot

Bcl-2 family expression and navitoclax response

Cell-based study · Panel of 39 human non-Hodgkin lymphoma cell lines [2]

Higher BCL-2 and NOXA expression correlated with sensitivity, while higher MCL-1 correlated with resistance. BCL-X and BCL-W expression did not significantly correlate with response in this panel.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Association of gene expression with ABT-263 responseExpression-response association BCL-2 and NOXA: sensitivity; MCL-1: resistance; BCL-X and BCL-W: no significant correlation reported.[2]

Literature-Reported Treatment Conditions

Method
Cell-line drug-response profiling and microarray analysis
Reported limits
Concentration series, exposure duration, response-assay reagent, vehicle and detailed culture conditions specific to the 39-line panel are not provided in the reviewed panel methods. No individual IC50 values estimated from the figure.
Methods and source locations

Compound reported in the paper: ABT-263 (Navitoclax); Compound label in the paper: ABT-263

Compound-level research evidence; no batch, polymorph or Adooq validation claim.

Figure 1A-B and legend; Methods: Microarray and predictive model; Results: High Bcl-2 expression correlates with sensitivity to ABT-263

Association of gene expression with ABT-263 response: Microarray expression and IC50 values averaged from three independent experiments; four-parameter curve fits; penalized lasso model with five-fold cross-validation — Figure 1A-B and legend; Methods: Microarray and predictive model; Results: High Bcl-2 expression correlates with sensitivity to ABT-263

Navitoclax (ABT-263) In Vivo Studies

In Sprague-Dawley rats, a single oral 5 mg/kg dose of ABT-263 gave bioavailability of 21.6 ± 2.0% and a terminal plasma half-life of 6.5 ± 0.65 h (mean ± SEM, n=3). The study used a 2 mg/kg IV reference dose and 10% DMSO in PEG-400. These are pharmacokinetic endpoints. [4]

In DoHH-2 lymphoma xenografts, oral navitoclax at 100 mg/kg/day for 14 days produced 44% tumor-growth inhibition and no objective responses. With a single 25 mg/kg IV bendamustine dose, tumor-growth inhibition reached 91% and overall response rate was 90% (n=10/group). Combination benefit was model-dependent: adding navitoclax to bendamustine–rituximab did not improve tumor response in SuDHL-4 xenografts. [5]

Single-dose pharmacokinetics in rats

Animal study · Sprague-Dawley rats; n=3 per route [4]

ABT-263 showed measurable oral exposure after a single 5 mg/kg dose. Dose-normalized oral bioavailability was 21.6 ± 2.0% (mean ± SEM).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Dose-normalized oral bioavailabilityF 21.6 ± 2.0%[4]
Oral terminal plasma elimination half-lifet1/2 6.5 ± 0.65 h[4]
IV terminal plasma elimination half-lifet1/2 8.4 ± 1.4 h[4]
IV plasma clearanceCLIV 0.15 ± 0.02 L/h/kg[4]
Steady-state distribution volumeVss 0.6 ± 0.13 L/kg[4]

Conditions shared by the study groups

Frequency
Once
Treatment course
Single dose; plasma sampled predose through 24 h
Vehicle
10% DMSO in PEG-400
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Oral ABT-263
5 mg/kg
IV reference arm at 2 mg/kgF 21.6 ± 2.0%; terminal half-life 6.5 ± 0.65 h (mean ± SEM).[4]
IV ABT-263 reference
2 mg/kg
Oral arm for bioavailability calculationTerminal half-life 8.4 ± 1.4 h; Vss 0.6 ± 0.13 L/kg; CLIV 0.15 ± 0.02 L/h/kg (mean ± SEM).[4]
Oral ABT-263
Model: Sprague-Dawley rats; n=3
Route: Oral gavage
Reported limits: Sex, age and body weight not stated in the reviewed rat methods.
IV ABT-263 reference
Model: Sprague-Dawley rats; n=3
Route: Slow IV bolus in jugular vein under light ether anesthesia
Reported limits: Sex, age and body weight not stated in the reviewed rat methods.
Methods and source locations

Compound reported in the paper: ABT-263 (Navitoclax); Compound label in the paper: ABT-263

Compound-level research evidence; no batch, polymorph or Adooq validation claim.

Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

Dose-normalized oral bioavailability: Plasma LC-MS analysis; oral/IV dose-normalized AUC0–∞ ratio; mean ± SEM, n=3 — Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

Oral terminal plasma elimination half-life: Serial plasma sampling through 24 h; mean ± SEM, n=3 — Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

IV terminal plasma elimination half-life: Plasma concentration-time modeling; mean ± SEM, n=3 — Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

IV plasma clearance: Dose/AUC0–∞; mean ± SEM, n=3 — Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

Steady-state distribution volume: Plasma clearance × mean residence time; mean ± SEM, n=3 — Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

Oral ABT-263 · Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

IV ABT-263 reference · Supplemental Material and Methods pp. 1-3, rat pharmacokinetics; Supplemental Table S1 p. 7, rat row and footnote b

Navitoclax with bendamustine in DoHH-2 xenografts

Animal study · DoHH-2 DLBCL flank xenografts in C.B.-17 scid mice; n=10/group [5]

Navitoclax alone produced modest tumor-growth inhibition without an objective response. Addition to bendamustine increased tumor-growth inhibition and overall response rate. TGI denotes tumor-growth inhibition; TGD is delay to a 1 cm³ tumor endpoint. CR requires tumor volume <25 mm³ for at least three measurements; ORR combines complete and partial responses.

Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Navitoclax alone
100 mg/kg/day
Matched vehicle groupTGI 44%; TGD 42%; CR 0%; ORR 0%.[5]
Bendamustine alone
25 mg/kg
Matched vehicle groupTGI 69%; TGD 69%; CR 0%; ORR 30%.[5]
Navitoclax plus bendamustine
Navitoclax 100 mg/kg/day + bendamustine 25 mg/kg
Vehicle and both monotherapy armsTGI 91%; TGD 146%; CR 20%; ORR 90%; reported cure fraction 0%.[5]
Vehicle controlComparator armComparator for tumor growth and response analyses.[5]
Navitoclax alone
Model: DoHH-2 DLBCL flank xenografts in C.B.-17 scid mice; n=10/group
Route: Oral gavage
Frequency: Once daily
Treatment course: 14 days
Vehicle: Phosal 50PG : PEG400 : ethanol mixture; proportions referenced to prior work and not restated
Reported limits: Navitoclax vehicle proportions and bendamustine vehicle not specified in this paper; sex and age not stated.
Bendamustine alone
Model: DoHH-2 DLBCL flank xenografts in C.B.-17 scid mice; n=10/group
Route: IV
Frequency: Once
Treatment course: Day 1
Reported limits: Bendamustine vehicle not specified.
Navitoclax plus bendamustine
Model: DoHH-2 DLBCL flank xenografts in C.B.-17 scid mice; n=10/group
Route: Navitoclax oral gavage; bendamustine IV
Frequency: Navitoclax daily; bendamustine once
Treatment course: Navitoclax 14 days; bendamustine day 1; navitoclax approximately 2 h before bendamustine
Vehicle: Phosal 50PG : PEG400 : ethanol mixture; proportions referenced to prior work and not restated for navitoclax
Reported limits: Bendamustine vehicle and navitoclax vehicle proportions not specified.
Vehicle control
Model: DoHH-2 DLBCL flank xenografts in C.B.-17 scid mice; n=10/group
Route: Routes matched to treatment
Treatment course: Matched treatment schedule
Vehicle: Dual vehicle control in Figure 1 legend
Reported limits: Full vehicle composition and individual control dosing schedule not restated.
Methods and source locations

Compound reported in the paper: ABT-263 (Navitoclax); Compound label in the paper: navitoclax

Compound-level research evidence; no batch, polymorph or Adooq validation claim.

Figure 1A and legend; Table 1 DoHH-2 rows and footnotes; Methods: Mouse xenograft trials and Statistical analysis

Navitoclax alone · Figure 1A and legend; Table 1 DoHH-2 rows and footnotes; Methods: Mouse xenograft trials and Statistical analysis

Bendamustine alone · Figure 1A and legend; Table 1 DoHH-2 rows and footnotes; Methods: Mouse xenograft trials and Statistical analysis

Navitoclax plus bendamustine · Figure 1A and legend; Table 1 DoHH-2 rows and footnotes; Methods: Mouse xenograft trials and Statistical analysis

Vehicle control · Figure 1A and legend; Table 1 DoHH-2 rows and footnotes; Methods: Mouse xenograft trials and Statistical analysis

No added efficacy over bendamustine–rituximab in SuDHL-4

Animal study · SuDHL-4 DLBCL flank xenografts in C.B.-17 scid-bg mice; n=10/group [5]

Adding navitoclax to bendamustine–rituximab did not improve the tumor response in this model.

Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Navitoclax alone
100 mg/kg/day
VehicleModest single-agent response described by the authors; exact effect size not extracted.[5]
Bendamustine plus rituximab
Bendamustine 25 mg/kg + rituximab 10 mg/kg
VehicleTumor growth inhibition and delayed regrowth; Figure 4 inset: TGI 82%, TGD 236%, ORR 20%.[5]
Navitoclax plus BR
Navitoclax 100 mg/kg/day + bendamustine 25 mg/kg + rituximab 10 mg/kg
BR alone, navitoclax alone and vehicleNo improvement over BR alone in the reported tumor-growth experiment.[5]
Vehicle controlComparator armComparator for tumor-growth analyses.[5]
Navitoclax alone
Model: SuDHL-4 DLBCL flank xenografts in C.B.-17 scid-bg mice; n=10/group
Route: Oral gavage
Frequency: Once daily
Treatment course: Days 21–34 after inoculation
Vehicle: Phosal 50PG : PEG400 : ethanol mixture; proportions referenced to prior work and not restated
Reported limits: Vehicle proportions, sex and age not stated.
Bendamustine plus rituximab
Model: SuDHL-4 DLBCL flank xenografts in C.B.-17 scid-bg mice; n=10/group
Route: IV for both
Frequency: Once
Treatment course: Day 21 after inoculation
Reported limits: IV vehicles not specified.
Navitoclax plus BR
Model: SuDHL-4 DLBCL flank xenografts in C.B.-17 scid-bg mice; n=10/group
Route: Navitoclax oral gavage; BR IV
Frequency: Navitoclax daily; BR once
Treatment course: Navitoclax days 21–34; BR day 21; navitoclax approximately 2 h before BR
Vehicle: Phosal 50PG : PEG400 : ethanol mixture; proportions referenced to prior work and not restated for navitoclax
Reported limits: No equivalence test or exact combination effect size reported in the reviewed text; IV vehicles not specified.
Vehicle control
Model: SuDHL-4 DLBCL flank xenografts in C.B.-17 scid-bg mice; n=10/group
Route: Routes matched to treatment
Treatment course: Matched treatment schedule
Vehicle: Triple vehicle control
Reported limits: Full vehicle composition and individual control dosing schedule not restated.
Methods and source locations

Compound reported in the paper: ABT-263 (Navitoclax); Compound label in the paper: navitoclax

Compound-level research evidence; no batch, polymorph or Adooq validation claim.

Figure 4 and legend; Results: Effects of myc and p53 on the efficacy of a combination of BR and navitoclax; Methods: Mouse xenograft trials

Navitoclax alone · Figure 4 and legend; Results: Effects of myc and p53 on the efficacy of a combination of BR and navitoclax; Methods: Mouse xenograft trials

Bendamustine plus rituximab · Figure 4 and legend; Results: Effects of myc and p53 on the efficacy of a combination of BR and navitoclax; Methods: Mouse xenograft trials

Navitoclax plus BR · Figure 4 and legend; Results: Effects of myc and p53 on the efficacy of a combination of BR and navitoclax; Methods: Mouse xenograft trials

Vehicle control · Figure 4 and legend; Results: Effects of myc and p53 on the efficacy of a combination of BR and navitoclax; Methods: Mouse xenograft trials

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 923564-51-6
Applications Bcl-2 inhibitor
Formula C47H55ClF3N5O6S3
Molecular Weight 974.6
Synonyms ABT263
SMILES
CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 89 mg/mL (91.31 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
6 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

From the Knowledge Base

Browse all articles

Navitoclax (ABT-263) Research References

  1. [1] Park CM, Bruncko M, Adickes J, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins Journal of medicinal chemistry (2008). PMID: 18841882 DOI: 10.1021/jm800669s Source material
  2. [2] Mérino D, Khaw SL, Glaser SP, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells Blood (2012). PMID: 22538851 DOI: 10.1182/blood-2011-12-400929 Source material
  3. [3] Wang B, Ni Z, Dai X, et al. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells Molecular cancer (2014). PMID: 24779770 DOI: 10.1186/1476-4598-13-98 Source material
  4. [4] Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer research (2008). PMID: 18451170 DOI: 10.1158/0008-5472.can-07-5836 Source material
  5. [5] Ackler S, Mitten MJ, Chen J, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo British journal of pharmacology (2012). PMID: 22624727 DOI: 10.1111/j.1476-5381.2012.02048.x Source material

Publications

26 publications citing this product

  1. Mikako Hirose, .et al. , Biosci Biotechnol Biochem, 2025, Dec 18;90(1):76-87 PMID: 41134023
  2. Song Han, .et al. , Neoplasia, 2025, Jan:59:101070 PMID: 39541736
  3. Abdel-Aziz S Shatat, .et al. , Purinergic Signal, 2024, May 27 PMID: 38801618
  4. Tristen Wright, .et al. , Mol Cell, 2024, Apr 4;84(7):1338-1353 PMID: 38503284
  5. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
  6. Yibo Wen, .et al. , Ren Fail, 2023, Dec;45(1):2194440 PMID: 37154092
  7. Rindert Missiaen, .et al. , Cell Metab, 2022, Aug 2;34(8):1151-1167 PMID: 35839757
  8. Ashlyn Parkhurst, .et al. , Cell Death Dis, 2022, Apr 28;13(4):410 PMID: 35484114
  9. Suzuki, Keiji, .et al. , Mutat Res Genet Toxicol Environ Mutagen, 2022, 876-877. 503448 PMID: 35483779
  10. Rotem Ben-Hamo, .et al. , Nat Commun, 2020, 11: 3296 PMID: 32620799
  11. Hua Xu, .et al. , Cancers (Basel), 2020, Apr; 12(4): 831 PMID: 32235588
  12. Hiroki Akiyama, .et al. , Cancers, 2020, 12 (2) PMID: 32050632
  13. Stephanie Ketterer, .et al. , Nat Commun, 2020, Oct 12;11(1):5133 PMID: 33046706
  14. Makoto Koyama, .et al. , Int J Oncol, 2020, Sep 2 PMID: 32901840
  15. Min Li, .et al. , Nat Commun, 2020, 11: 4051 PMID: 32792548
  16. Hamzehlou S, .et al. , Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
  17. Momeny M, .et al. , Cell Oncol (Dordr), 2019, Apr 25 PMID: 31025257
  18. Anderson R, .et al. , EMBO J, 2019, Feb 8. pii: e100492 PMID: 30737259
  19. Shinya Ishida, .et al. , Oncotarget, 2018, Jun 1; 9(42): 26834-26851 PMID: 29928488
  20. Rhys Anderson, .et al. , bioRxiv, 2018, 2018
  21. Ryuta Mikawa, .et al. , Aging Cell, 2018, Oct; 17(5): e12827 PMID: 30058137
  22. Joo Sang Lee, .et al. , Nat Commun, 2018, 9: 2546 PMID: 29959327
  23. Toshiyuki Sumi, .et al. , Int J Oncol, 2018, Jul; 53(1): 33-46 PMID: 29658609
  24. Wei TW, .et al. , Cancer Res, 2017, Jan 15;77(2):494-508 PMID: 28069801
  25. Yusuke Takagi, .et al. , Cancer Sci, 2016, Sep; 107(9): 1270-1280 PMID: 27348272
  26. Matsumoto M, .et al. , Biochem Biophys Res Commun, 2016, Apr 29;473(2):490-6 PMID: 26996126

Showing 10 of 26 publications

Added to your cart

View Cart Checkout
Loading...